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Flow cytometryRecent progress has been made in understanding the mechanisms of antitumor immune responses, which may
further clarify the immune status of cancer patients. In this study, we performed a detailed evaluation of the im-
munological status of 47 patients with advanced solid cancer, who had received no immunosuppressive treat-
ment, and compared the results with 32 healthy subjects. Flow-cytometry data for peripheral blood were
obtained using 19monoclonal antibodies against various cell surface and intracellular molecules. Absolute num-
bers of T cells, several T cell subsets, B cells, and NK cells were signiﬁcantly decreased in patients compared with
healthy subjects. The percentage of CD27+CD45RA+ T cells was lower and that of CD27−CD45RA− T cells was
higher in patients comparedwith controls. Regulatory and type 2 helper T cells were elevated in patients relative
to healthy subjects. The percentage of perforin+ NK cells was signiﬁcantly lower in patients than in controls.
These results suggest a dysfunctional anti-tumor immune response in cancer patients. Furthermore, peripheral
blood from 26 of 47 cancer patients was analyzed after adoptive T cell immunotherapy (ATI). ATI increased
the number of T cell subsets, but not B and NK cells. The number and percentage of regulatory T cells decreased
signiﬁcantly. These results suggest that ATI can restore impaired and imbalanced T cell immune status.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-N D  license.1. Introduction
The concept that the immune system recognizes and eliminates
tumor cells iswell accepted [1,2]. Dysfunction of host systemic immunity,
especially cell-mediated immunity (CMI), may be involved in the
establishment of advanced cancer. Peripheral blood (PB) is widely used
to assess systemic immune function. Previous studies noted that the
number of lymphocytes and levels of several cytokines involved in
CMI were reduced in PB from cancer patients [3–5]. The cytokine proﬁle
of CD4+ helper T cells revealed an imbalance between T helper (Th) 1
cells that produce interferon (IFN)-γ, and Th2 cells that produce interleu-
kin (IL)-4. The shift from Th1 to Th2 was previously observed in cancer
patients [5–7]. Regulatory T (Treg) cells have been reported to be in-
creased in several types of cancer patients [8]. T cells can be divided
into various subpopulations that differ in their surface or intracellular81 35215 0890.
. Open access under CC BY-NC-N D  licemarkers. Flow cytometry (FCM) to detect those markers might have the
potential to clarify the immune status of cancer patients.
The beneﬁts of immunotherapy for human cancer have gradually
gained acceptance. In 2010, the United States Food and Drug Adminis-
tration approved sipuleucel-T, an autologous cellular immunotherapy
for the treatment of prostate cancer [9]. Sipuleucel-T is considered to
be an active component of antigen-presenting cells that induces a spe-
ciﬁc immune response against prostatic acid phosphatase [10]. Admin-
istration of tumor-inﬁltrating lymphocytes after lymphodepleting
pretreatment was shown to mediate tumor regression in patients
with metastatic melanoma [11]. Chimeric antigen receptor-modiﬁed
T cells targeting CD19 were shown to be beneﬁcial in patients with
chronic lymphocytic leukemia [12] and acute lymphoid leukemia [13].
Alternatively, a non-speciﬁc immunotherapy approach using autolo-
gous T or NK cells was also efﬁcacious [14–18]. We recently reported a
survival advantage of adoptive T cell immunotherapy (ATI) in advanced
lung cancer patients [19]. In these clinical studies, the accurate assessment
of immune effects in patients is of particular importance to understanding
the impact of treatment. In the case of antigen-speciﬁc approaches,
antigen-speciﬁc immune responses such as cytotoxic T-cell responses
are one of the most important parameters for assessment. In contrast,
there are no reliable parameters for non-speciﬁc immunotherapy
regimes.nse.
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status of advanced solid cancer patients who had not received prior
immunosuppressive treatment, using FCM, and compared it with
healthy subjects. In addition, changes in the immunological status of
cancer patients receiving ATI were studied. We report that impaired
and imbalanced CMI in cancer patients might be restored by ATI.
2. Materials and methods
2.1. Patients and healthy subjects
Forty-seven patients with histologically conﬁrmed cancer of various
organs and a performance status of 0, 1, or 2 were enrolled in the study.
All patients had unresectable advanced solid cancers and an extended
primary tumor with multiple metastases. Patients were excluded if
they had an infectious disease, interstitial pneumonia, or autoimmune
disease, or if they had received immunosuppressive treatments such
as chemotherapy, irradiation, or adrenocorticosteroid hormone in the
previous 60 days. Patient characteristics and primary organs are
shown in Table 1. Ages ranged from 43 to 84 years, with a median of
69 years. The performance status was 0 in 27, 1 in 17 and 2 in three
patients. Thirty-two healthy subjects, aged 40–81 years, were used as
controls. The research ethics committee of the Seta Clinic Group,
Tokyo, Japan, approved this study. Written informed consent was
obtained from all patients and healthy subjects prior to blood collection.
2.2. FCM of peripheral blood mononuclear cells (PBMCs)
Heparinized PB was collected from patients and healthy subjects.
We previously determined the inﬂuence of temperature and time
from blood collection to the start of assay on the results of FCM, and
established that storage of PB at 18–22 °C for 1 day followed by pheno-
typic analyses provided consistent results.
Phenotypic analysis of PBMCswas performed bywhole-blood stain-
ing with OptiLyse C lysis solution. Absolute cell numbers were deter-
mined using Flow-Count™ ﬂuorosphere internal standard beads. The
OptiLyse C, Flow-Count beads, and monoclonal antibodies (mAbs)
against CD3, CD4, CD8, CD14, CD16, CD19, CD27, CD45, CD45RA,Table 1
Patient characteristics.
Number of cancer
patients
Number of cancer patients
after adoptive T cell therapy
Age b40 years 0 0
41–50 years 2 1
51–60 years 13 9
61–70 years 12 3
71–80 years 16 12
N80 years 4 1
Median 69 70
Range 43–84 43–83
Gender Male 16 8
Female 31 18
Primary tumor site Lung 14 7
Uterus 6 4
Colon 4 2
Esophagus 3 2
Pharynx 3 2
Breast 3 2
Stomach 3 0
Ovary 2 2
Pancreas 2 0
Prostate 2 2
Bile duct 2 2
Othersa 3 1
Performance status 0 27 16
1 17 9
2 3 1
a Rectum, vulva or retroperitoneum one each.CD56, TCR pan αβ, TCR pan γδ, TCR Vγ9 and NKG2D were purchased
from Beckman Coulter (Brea, CA, USA). Lymphoprep™ (Axis-Shield
PoC AS, Oslo, Norway) was used with gradient centrifugation to isolate
PBMCs. Isolated PBMCs were used for cytokine production assays,
Foxp3, and perforin staining. For Foxp3 staining, PBMCs were ﬁxed
and permeabilized using a ﬁxation/permeabilization kit (BioLegend,
San Diego, CA, USA) according to the manufacturer's protocol, and
Foxp3 was stained with anti-Foxp3 mAb (clone 259D, BioLegend). For
perforin staining, PBMCs were ﬁxed and permeabilized using the
IntraPrep™ leukocytic permeabilization reagent (Beckman Coulter),
and perforin stained by anti-perforin mAb (eBioscience, San Diego, CA,
USA). A Cytomics FC500 and/or Gallios ﬂow cytometer (Beckman
Coulter) was used for data acquisition, and the data were analyzed
with CXP and/or Kaluza software (Beckman Coulter).
2.3. Cytokine production assay
For analysis of intracellular cytokine production, PBMCs were
suspended in RPMI1640 medium (Invitrogen, Grand Island, NY, USA)
supplementedwith 10% heat-inactivated fetal bovine serum (Invitrogen)
containing 20 ng/mL phorbol 12-myristate 13-acetate (Sigma-Aldrich,
St. Louis, MO, USA), 2 μg/mL ionomycin (Sigma-Aldrich), and 20 μg/mL
brefeldin A (Sigma-Aldrich), at 1 × 106 cells/mL. Cells were incubated
at 37 °C in a humidiﬁed atmosphere with 5% CO2 for 4 h for the
IFN-γ/IL-4 assay or 5 h for the IFN-γ/IL-17 assay. Activated cells were
ﬁxed and permeabilized using IntraPrep™. Intracellular cytokines were
stained with anti-IFN-γ (Beckman Coulter), IL-4 (Beckman Coulter), or
IL-17A mAbs (BioLegend).
2.4. Adoptive T cell immunotherapy
The method for generating activated T cells for treatment
was described previously [17,20]. Brieﬂy, PBMCs were cultured with
immobilized anti-CD3 antibody and IL-2 for approximately 14 days,
and 5 × 109 lymphocytes were harvested. Expanded lymphocytes
were infused intravenously and injections were repeated every
2 weeks. The cultured lymphocytes consisted of mainly CD8+ or
CD4+ T cells with small percentages of NK cells and γδ T cells [21].
PBwas obtained for FCManalyses just before theﬁrst infusion. At the
start of treatment, conventional therapies such as chemotherapy or ra-
diotherapy were not indicated in any patients. Tumors were evaluated
by radiology after ﬁve rounds of ATI. Some patients showed signs of
disease progression during ATI, necessitating the use of conventional
therapies in combination with ATI. Twenty-six of 47 patients received
more than ﬁve courses of ATI in the absence of conventional therapy,
andwere thus evaluated after ATI. In these 26 patients, PBwas obtained
for FCM analysis 2 weeks after the ﬁfth ATI infusion.
2.5. Statistical analysis
Statistical analysis was conducted using JMP 6.0.0 software (SAS
Institute, Cary, NC, USA). Wilcoxon's rank sum test was used to analyze
the data in Table 2 andWilcoxon's signed-rank test was used to analyze
the data in Table 3. A value of P b 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Phenotypic characterization of PBMCs
We measured the percentages and absolute numbers of PBMCs
collected from 47 cancer patients. The phenotypes were compared
with those of 32 healthy control subjects. The statistical values are
shown in Table 2 and the important parameters are represented
diagrammatically in Figs. 1–3. The numbers of CD45+ leukocytes were
similar in patients and controls, although the number and percentage
Table 2
Percentages and absolute numbers of immune cells in blood of 32 healthy subjects and 47 cancer patients.
Percentage (%) Number (cells/μL)
Median Wilcoxon's
rank sum test
Median Wilcoxon's
rank sum test
Healthy
subjects
Cancer
patients
P value
(prob N |Z|)
Healthy subjects Cancer
patients
P value
(prob N |Z|)
Leukocytes CD45+ – – – 4817 4874 0.488
[CD45+ gated] PBMC 43.1 31.5 b0.001 2032 1444 b0.001
[PBMC gated] CD3+ 58.3 48.9 b0.001 1218 684 b0.001
[PBMC gated] CD3−CD56+ 12.5 10.2 0.108 272 149 b0.001
[PBMC gated] CD19+ 10.5 8.6 0.214 216 132 b0.001
[PBMC gated] CD14+ 10.3 17.1 b0.001 208 266 0.083
T cell subsets [PBMC gated] CD3+TCR pan αβ+ 54.5 45.4 b0.001 1133 602 b0.001
[PBMC gated] CD3+TCR pan γδ+ 2.3 1.6 0.301 51 26 0.006
[PBMC gated] CD3+TCR Vγ9+ 1.6 1.0 0.087 29 14 0.002
[PBMC gated] CD3+CD56+ 8.0 3.6 b0.001 170 48 b0.001
[PBMC & CD3+ gated] CD4+CD8− 62.5 57.0 0.283 711 354 b0.001
[PBMC & CD3+ gated] CD4−CD8+ 31.5 32.2 0.562 395 236 b0.001
CD4/CD8 ratio 2.0 1.9 0.450 – – –
[PBMC & CD3+ gated] CD27−CD45RA+ 5.5 8.9 0.142 71 62 0.292
[PBMC & CD3+ gated] CD27+CD45RA+ 25.5 13.5 b0.001 290 85 b0.001
[PBMC & CD3+ gated] CD27−CD45RA− 12.8 18.9 0.016 154 97 0.033
[PBMC & CD3+ gated] CD27+CD45RA− 55.6 55.1 0.992 629 393 b0.001
CD4+ T cell subsets [CD3+CD4+ gated] IFN-γ+IL4− 14.6 10.5 0.048 98 45 b0.001
[CD3+CD4+ gated] IFN-γ−IL4+ 3.2 4.3 0.022 22 18 0.016
[CD3+CD4+ gated] IL17+ 1.3 1.4 0.764 9 6 b0.001
Th1/Th2 ratio 4.6 2.6 0.001 – – –
[CD3+CD4+ gated] Foxp3+ 3.8 8.6 b0.001 29 32 0.846
Expression of CD16,
NKG2D and perforin
[PBMC & CD3+ gated] CD16+ 2.2 3.1 0.049 26 25 0.107
[PBMC & CD3−CD56+ gated] CD16+ 67.3 74.4 0.241 190 103 b0.001
[PBMC & CD3+CD56+ gated] CD16+ 3.2 5.5 0.005 6 2 0.001
[PBMC & CD3+ gated] NKG2D+ 34.7 37.1 0.396 421 290 b0.001
[PBMC & CD3−CD56+ gated] NKG2D+ 57.5 61.8 0.294 162 88 b0.001
[PBMC & CD3+CD56+ gated] NKG2D+ 37.7 50.7 0.052 66 21 b0.001
[PBMC & CD3−CD56+ gated] perforin+ 90.3 82.8 0.005 242 119 b0.001
PBMC, peripheral blood mononuclear cell.
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age and number of CD3+ cells among PBMCs and the numbers of CD3−
CD56+ and CD19+ cells were signiﬁcantly lower in cancer patients than
in controls (P b 0.001). In contrast, the percentage of CD14+ cells
among PBMCs was signiﬁcantly higher in patients than in controls
(P b 0.001).
3.2. T cell subsets
We measured the absolute numbers and percentages of T cell
subsets (Fig. 2). The numbers of CD3+TCRαβ+, CD3+TCRγδ+,
CD3+TCRVγ9+, CD3+CD56+, CD3+CD4+CD8−, and CD3+CD4−CD8+
cells were signiﬁcantly lower in patients (P b 0.001, P = 0.006,
P = 0.002, P b 0.001, P b 0.001, P b 0.001, respectively) compared
with controls. The percentages of CD3+TCRαβ+ and CD3+CD56+
PBMCswere also signiﬁcantly lower in patients (P b 0.001) than in con-
trols. Four T cell subpopulations were distinguished based on CD27 and
CD45RA expression. The absolute number of cells in each subpopulation
tended to be lower in patients than in controls. The percentage of
CD27+CD45RA+ T cells was signiﬁcantly lower, and the percentage of
CD27−CD45RA− T cells was signiﬁcantly higher in patients (P b 0.001,
P = 0.016) compared with controls.
3.3. Subsets of CD4+ T cells
We analyzed the intracellular cytokine proﬁle of CD4+ T cells
and the number of regulatory T cells to characterize their anti-tumor
function (Fig. 3). The numbers of CD3+CD4+IFN-γ+IL-4− (Th1),
CD3+CD4+IFN-γ−IL-4+ (Th2), and CD3+CD4+IL-17+ (Th17) cells
were signiﬁcantly lower in patients than in healthy subjects
(P b 0.001, P = 0.016, P b 0.001, respectively). The percentage of Th1
cells among CD3+CD4+ cells was signiﬁcantly lower (P = 0.048), andthat of Th2 cells was signiﬁcantly higher, in patients (P = 0.022) com-
pared with healthy subjects. The Th1/Th2 ratio was lower in patients
than in healthy subjects (P = 0.001). The overall percentage of
Th17 cells was similar in both groups, but an elevated-Th17 subgroup
was observed in patients (data not shown). The number of Treg cells
was similar, but the percentage of Foxp3+ CD3+CD4+ Treg cells was
signiﬁcantly higher in patients (P = 0.001), compared with controls.
3.4. Expression of CD16, NKG2D, and perforin
The number of CD3+/−CD56+CD16+ cells was lower in patients
(P ≤ 0.001), though the percentage of CD16+ cells among CD3+CD56+
cells was signiﬁcantly higher (P = 0.005) than in healthy subjects. The
number of CD3+/−CD56+/−NKG2D+ cells was signiﬁcantly lower
in patients (P b 0.001), though the percentages of NKG2D+ cells
among CD3+/−CD56+/− cells were similar. The number and percentage
of CD3−CD56+perforin+ cells was lower in patients (P b 0.001,
P = 0.005) than in healthy subjects.
3.5. Changes in the number and percentage of immune cells in PB after ATI
To evaluate the anti-tumoral immune responses induced by ATI,
we analyzed PB from 26 patients collected 2 weeks after the ﬁfth trans-
fusion. The statistical values are shown in Table 3 and the important pa-
rameters are represented diagrammatically in Fig. 4. The total number
of cells infused from the ﬁrst to ﬁfth ATI ranged from 1.8 to 3.6 × 1010
cells (mean = 3.1 × 1010 cells). The numbers of CD45+ leukocytes,
PBMCs, and CD3+ cells in PB increased signiﬁcantly after ﬁve infusions
(P = 0.010, P = 0.001, P b 0.001, respectively), whereas the numbers
of CD3−CD56+ cells, CD19+ cells and CD14+ cells remainedunchanged.
The percentages and numbers of TCRαβ+, TCRγδ+, TCRVγ9+, and
CD4−CD8+ T cells among PBMCs increased signiﬁcantly after ATI
Table 3
Percentages and absolute numbers of immune cells in blood collected from 26 cancer patients before the ﬁrst ATI and 2 weeks after the ﬁfth ATI treatment.
Percentage (%) Number (cells/μL)
Median Wilcoxon's
signed-rank test
Median Wilcoxon's
signed-rank test
Before ATI After ATI P value (prob N |Z|) Before ATI After ATI P value (prob N |Z|)
Leukocytes CD45+ – – – 4391 5071 0.010
[CD45+ gated] PBMC 32.9 35.6 0.094 1608 1844 0.001
[PBMC gated] CD3+ 51.8 57.5 b0.001 786 1102 b0.001
[PBMC gated] CD3−CD56+ 10.1 9.0 0.003 147 146 0.931
[PBMC gated] CD19+ 10.1 9.7 0.001 144 172 0.413
[PBMC gated] CD14+ 16.1 15.2 0.307 231 295 0.070
T cell subsets [PBMC gated] CD3+TCR pan αβ+ 47.3 50.0 0.001 752 976 b0.001
[PBMC gated] CD3+TCR pan γδ+ 2.4 3.3 0.001 24 64 b0.001
[PBMC gated] CD3+TCR Vγ9+ 1.0 2.3 b0.001 14 42 b0.001
[PBMC gated] CD3+CD56+ 3.4 3.6 0.708 45 58 0.278
[PBMC & CD3+ gated] CD4+CD8− 61.1 44.3 b0.001 377 416 0.097
[PBMC & CD3+ gated] CD4−CD8+ 30.5 41.2 b0.001 255 475 b0.001
CD4/CD8 ratio 2.0 1.2 b0.001 – – –
[PBMC & CD3+ gated] CD27−CD45RA+ 6.4 8.0 0.565 55 89 0.028
[PBMC & CD3+ gated] CD27+CD45RA+ 15.9 11.0 0.033 108 122 0.167
[PBMC & CD3+ gated] CD27−CD45RA− 17.6 25.9 b0.001 106 268 b0.001
[PBMC & CD3+ gated] CD27+CD45RA− 56.9 48.5 b0.001 428 462 0.003
CD4+ T cell subsets [CD3+CD4+ gated] IFN-γ+IL4− 12.0 13.2 0.748 49 62 0.225
[CD3+CD4+ gated] IFN-γ−IL4+ 5.0 5.5 0.192 19 26 0.012
[CD3+CD4+ gated] IL17+ 1.5 1.4 0.714 6 7 0.302
Th1/Th2 ratio 2.5 2.4 0.495 – – –
[CD3+CD4+ gated] Foxp3+ 9.2 5.9 b0.001 38 25 0.022
Expression of CD16,
NKG2D and perforin
[PBMC & CD3+ gated] CD16+ 3.6 1.8 b0.001 28 20 0.561
[PBMC & CD3−CD56+ gated] CD16+ 73.5 71.5 0.805 115 99 0.767
[PBMC & CD3+CD56+ gated] CD16+ 5.6 4.0 0.039 3 3 0.836
[PBMC & CD3+ gated] NKG2D+ 36.3 49.7 b0.001 323 514 b0.001
[PBMC & CD3−CD56+ gated] NKG2D+ 61.7 66.7 0.480 97 93 0.569
[PBMC & CD3+CD56+ gated] NKG2D+ 43.1 63.2 0.018 26 26 0.133
[PBMC & CD3−CD56+ gated] perforin+ 83.4 79.4 0.434 126 109 0.912
ATI, adoptive T cell immunotherapy; PBMC, peripheral blood mononuclear cell.
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ratio decreased signiﬁcantly after ATI (P b 0.001). The number
of CD27−/CD45RA− T cells increased signiﬁcantly following ATI
(P b 0.001), whereas the number of CD27+CD45RA+ cells was un-
changed. The percentage of CD27−CD45RA− T cells increased signiﬁcant-
ly (P b 0.001) after ATI, whereas the percentage of CD27+CD45RA+ T
cells decreased (P = 0.033). There were no differences in the percent-
ages of Th1, Th2 and Th17 cells among the CD3+CD4+ subset, though
the number of Th2 cells was elevated after ATI (P = 0.005). The percent-
age and number of Treg cells decreased following ATI. The percentages of
CD16+ cells among CD3+ and CD3+CD56+cells decreased signiﬁcantly
(P b 0.001, P = 0.039), though their absolute numbers were unaltered.
The percentages of NKG2D+ cells among the CD3+andCD3+CD56+ sub-
sets were signiﬁcantly increased (P b 0.001, P = 0.018), while the num-
ber of NKG2D+CD3+ cells was also signiﬁcantly increased (P b 0.001).
Neither the percentage nor the number of perforin+ cells was altered
by ATI.
4. Discussion
The anti-cancer immune response is composed of an orchestrated
combination of various immune cells and cytokines. We performed a
detailed examination of the immune status in 47 patients with
advanced solid cancers with primary sites in various organs. All had
unresectable advanced cancer, a performance status of 0, 1 or 2 and
adequate physiological functions. Patients with advanced cancer often
need conventional therapies; however, such therapies might have
toxic effects such as myelosuppression, which could affect the treat-
ment results. In this study, we therefore only analyzed data from
patients who did not receive such conventional therapies before or
during ATI. To investigate the potential effects of ATI on immune status,
we examined PBMCs 2 weeks after theﬁfth course of ATI. Among the 47
patients, 21 patients required conventional therapy before the ﬁfth ATIinfusion, and the results of the remaining26patientswho continuedATI
without conventional therapies were thus used to analyze the effects of
ATI.
Immunological status in cancer was determined by comparing FCM
results between patients and healthy subjects. The numbers of CD45+
leukocytes were similar in patients and controls, although the number
of PBMCs was signiﬁcantly lower in patients, indicating that patients
had signiﬁcantly increased numbers of granulocytes. The numbers of T
cells, including several subsets, B cells, and NK cells, were signiﬁcantly
lower, and the percentage ofmonocytes among PBMCswas signiﬁcantly
higher in patients compared with healthy subjects. These ﬁndings are
similar to those in previous reports [2,3,22] and indicate a total decrease
of lymphocytes. T cells, including αβ, γδ, CD4+ and CD8+ T cells, are a
major component of the cells used in ATI, prompting us to perform a de-
tailed evaluation of T cell subsets. The numbers of cells in these T cell
subsets were lower in cancer patients, suggesting total T cell impair-
ment. Furthermore, T cells can be divided into subpopulations based
on cell surfacemarkers, such as CD27 and CD45RA [23]. The percentage
of CD27+CD45RA+-naïve cells, which demonstrate a high proliferation
rate, was lower in patients than in healthy controls. In contrast, the per-
centage of CD27−CD45RA− effector memory cells, which proliferate
poorly but produce IFN-γ and exert antitumor immunity, was higher
in patients. This suggests a shift from naïve to effector cells in patients.
A similar result was previously reported in patients with squamous
cell carcinoma of the head and neck [24]. However, the result is contro-
versial, because another report showed that numbers of naïve,memory,
and effector CD8+ T subsets did not differ between healthy donors and
cancer patients [25]. The percentage of IFN-γ+IL-4− Th1 cells among
CD4+ T cells was lower, but that of IFN-γ−IL-4+ Th2 cells was higher
in patients compared with controls. These lead to lower Th1/Th2 ratios
in patients. Although the number of Th2 which is a part of CD4+ T cells
was signiﬁcantly lower in patients, the difference was smaller than that
of Th1. These results indicate that the whole CD4+ T response might be
Fig. 1. Box plots of percentages and absolute numbers of representative leukocytes from cancer patients and healthy subjects. Percentages of leukocytes in PBMC (upper row) and absolute
numbers of leukocytes in peripheral blood (lower row) in 47 cancer patients and 32 healthy subjectswere analyzed. The lengths of the boxes represent the interquartile ranges; horizontal
lines represent the medians; vertical lines extend to the minimum and maximum values. *P b 0.05.
Fig. 2. Box plots of percentages and absolute numbers of representative T cell subsets from cancer patients and healthy subjects. Percentages (upper row) and absolute numbers
(lower row) of T cell subsets in PB from 47 cancer patients and 32 healthy subjects were analyzed. The lengths of the boxes represent the interquartile ranges; horizontal lines represent
the medians; vertical lines extend to the minimum and maximum values. *P b 0.05.
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Fig. 3. Box plots of percentages and absolute numbers of representative CD4+ T cells subsets and perforin+ NK cells from cancer patients and healthy subjects. Percentages (upper row)
and absolute numbers (lower row) of Th1, Th2, Treg and perforin+ NK cells in PB from 47 cancer patients and 32 healthy subjects were analyzed. The lengths of the boxes represent the
interquartile ranges; horizontal lines represent the medians; vertical lines extend to the minimum and maximum values. *P b 0.05.
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tients. This imbalance has been reported previously, andwas conﬁrmed
in the current study [6,7]. In terms of the immune regulation, the
percentages of Th1 and Th2 cells among CD4+ T cells might help to
explain the balance between CMI and humoral immunity. Humoral
immunity is predominant in cancer patients. IL-17 is known to be in-
volved in autoimmune disease [18]. IL-17-producing CD3+CD4+ cells
are known as Th17 cells, and the role of Th17 cells in malignancy
is currently under debate [26]. We attempted to examine Th17 cell
numbers in both patients and healthy subjects, but their numbers
were unfortunately too low to analyze. Several reports have demon-
strated increases in Treg cells in PB or in tumor-inﬁltrating lympho-
cytes from cancer patients [27–29]; our study also revealed that the
percentage of Foxp3+ CD4+ T cells was higher in patients than in
healthy controls. These observations suggest an inhibitory effect
on CMI in cancer patients. Expression of surface molecules involved
in anti-tumor cytotoxic activity was also examined. The percentage
of CD16+ T cells was elevated in patients, though the percentages
of NKG2D+ T cells were similar in patients and healthy subjects.
These observations differ from previous reports that showed CD16 or
NKG2D expression was lower in cancer patients [30,31]. Perforin is a
cytolytic protein involved in NK cell cytotoxic activity. The percentage
of perforin+ NK cells was lower in patients, indicating dysfunctional
NK cell cytotoxic activity.
We previously reported the phenotypes of cells used for ATI infusion
in 678 patients [21]. Approximately 90% of cultured cells were
αβ T cells, consisting of 30 ± 15% CD3+CD4+ T cells, 61 ± 15%
CD3+CD8+ cells, 7 ± 8% γδ T cells, and 7 ± 10% CD3−CD56+ NK
cells. The effect of ATI on the immune status of patients was determined
in this study by comparing FCM results before and after treatment. The
numbers of T cells and their subsets in PB increased signiﬁcantly, whilethose of B cells, NK cells, andmonocytes did not. Between thebefore and
after treatment, ameanof 3.1 × 1010 expanded T cellswere infused into
26 patients. The total volume of blood in a human is approximately
5000 mL, and the median number of T cells in patient PB prior to treat-
ment was 786 cells/μL. Accordingly, the number of T cells in patient
whole PB was estimated to be 3.9 × 109 cells. Thus, the total number
of T cells infused was estimated to be eight times greater than the
total number of T cells in whole PB. A signiﬁcant increase in T cell num-
bers to 1102 cells/μL in PBmight be explained by the infused cells circu-
lating around the body. The changes in percentages of CD4+, CD8+,
CD27+/−CD45RA+/−, and NKG2D+ T cells might have resulted from
the different percentages of these phenotypes in the infused cells from
PBMCs. The numbers of T cell subsets in PB were elevated following
ATI, whereas the number of Foxp3+ CD4+ T cells in PB signiﬁcantly de-
creased to almost healthy-subject levels (Wilcoxon's rank sum test
P = 0.189). Another recent study investigated the number and per-
centage of Foxp3+ CD4+ T cells in PB from patients with advanced pan-
creatic cancer before and after ATI. They reported no signiﬁcant change
in either the number or percentage of Treg cells following ATI [32].
However, most patients in that study had received prior chemotherapy,
as well as combined treatments, and chemotherapy is known to have a
marked effect on immune status [33]. The number of PBMCs and their
phenotypes differed depending on the time from chemotherapy, mak-
ing evaluation of the effect of ATI on immune status difﬁcult. In the cur-
rent study, we demonstrated a reduction in the number of Treg cells
following ATI in patients who had not received immunosuppressive
treatment. This marked reduction of Foxp3+ CD4+ T cells in PB might
represent a novel mechanism of ATI, and is worthy of further investiga-
tion. Analyses of tumor biopsy specimens might improve our under-
standing of the anti-tumor immune response. However, this approach
is impractical, given that repeated biopsies impose a heavy burden on
Fig. 4. Changes in immunological status after ATI. Absolute numbers (upper andmiddle row) and percentages (lower row) of indicated cells in PB from patients were analyzed before the
ﬁrst ATI and 2 weeks after theﬁfth ATI treatment. Each connected dot represents one of the 26 patients. The lengths of the red boxes represent the interquartile ranges; horizontal red lines
represent the medians; vertical red lines extend to the minimum and maximum values. *P b 0.05.
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the PB, as well as in the tumor site in patients with invasive breast or
pancreatic cancer [34]. The signiﬁcant decrease in Treg cells in the PB
following ATI observed in this study thus suggests that Treg cells may
also be decreased in the tumor.
It is important to determine whether the change in immunolog-
ical status by ATI was associated with clinical outcome. However,
this issue could not be clariﬁed because the patients in this study
had cancers of various organs, and the prognosis thus differed for
each patient despite the immunological responses observed. It
was previously reported that insufﬁcient lymphocyte numbers
might have a negative effect on vaccine therapy for cancer [35,36].
The combination of ATI and antigen-speciﬁc immunotherapy
might prove beneﬁcial by restoring the number of lymphocytesand imbalanced T cell immune status in patients. Furthermore, the ﬁnd-
ings of this study indicate a potential application for immunological
monitoring of other immunotherapies that enhance T cell immune re-
sponses in a non-antigen-speciﬁc fashion, including anti-CTLA4 mAb,
ipilimumab [37], anti-programmed death 1 (PD-1) antibody [38] and
anti-PD-1 ligand antibodies [39].
In summary, the cellular immunological status was impaired in
patients with advanced solid cancer, and the impaired T cell immune
status was restored by ATI infusions. FCM analysis allows the assess-
ment of cancer patient immune status following immunotherapy.
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